MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MACROGENICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.33+0.08 (+2.46%)
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
Macrogenics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Macrogenics | Industry median |
|---|---|---|
| Market Cap | $212.12M | $166.30M |
| Enterprise Value | $98.21M | $88.19M |
| PS Ratio | 1.27 | 3.65 |
| PB Ratio | 4.95 | 2.03 |
| P/TBV Ratio | 4.95 | 2.29 |
Enterprise value
| Measure | Macrogenics | Industry median |
|---|---|---|
| EV / Sales | 0.59 | 2.51 |
Income (trailing twelve months)
| Measure | Macrogenics | Industry median |
|---|---|---|
| Revenue | $167.67M | $58.34M |
| Operating Income | -$40.75M | -$21.40M |
| Net Income | -$14.59M | -$22.46M |
| EBITDA | -$34.86M | -$16.91M |
| EPS (Diluted) | -$0.22 | -$0.83 |
Margins
| Measure | Macrogenics | Industry median |
|---|---|---|
| Operating Margin | -24.3% | -44.0% |
| Profit Margin | -8.70% | -40.2% |
| EBITDA Margin | -20.8% | -30.2% |
| FCF Margin | -39.1% | -9.27% |
Returns
| Measure | Macrogenics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -32.6% | -53.2% |
| Return on Assets (ROA) | -4.94% | -40.9% |
| Return on Capital Employed (ROCE) | -17.2% | -38.1% |
Growth
| Measure | Macrogenics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.7% | 5.96% |
| Revenue Growth (3Y CAGR) | -0.54% | 2.25% |
| Revenue Growth (5Y CAGR) | 7.35% | 6.48% |
Balance sheet
| Measure | Macrogenics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $113.91M | $61.43M |
| Net Cash (Debt) | $113.91M | $15.35M |
| Net Cash Per Share | $1.79 | $0.66 |
| Equity (Book Value) | $42.87M | $49.09M |
| Book Value Per Share | $0.67 | $1.37 |
| Tangible Book Value | $42.87M | $23.52M |
| Working Capital | $212.87M | $76.81M |
Financial position
| Measure | Macrogenics | Industry median |
|---|---|---|
| Current Ratio | 2.96 | 3.34 |
| Quick Ratio | 1.27 | 2.44 |
| Interest Coverage | -2.41 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Macrogenics | Industry median |
|---|---|---|
| Operating Cash Flow | -$63.72M | -$12.35M |
| Capital Expenditures | -$1.82M | -$1.08M |
| Free Cash Flow | -$65.54M | -$20.22M |
| FCF Per Share | -$1.03 | -$0.42 |
Efficiency
| Measure | Macrogenics | Industry median |
|---|---|---|
| Asset Turnover | 0.57 | 0.39 |
| Revenue Per Employee | $572.26K | $404.87K |
| Profits Per Employee | -$49.80K | -$703.34K |
| Employee Count | 293 | 74 |
Dividends and yields
| Measure | Macrogenics | Industry median |
|---|---|---|
| Earnings Yield | -6.88% | -23.3% |
| FCF Yield | -30.9% | -8.72% |
Shares
| Measure | Macrogenics | Industry median |
|---|---|---|
| Shares Outstanding | 63,700,200 | 58,127,000 |
| Shares Change (YoY) | 0.74% | 10.9% |
| Shares Change (QoQ) | 0.13% | 0.54% |
| Float | 59,776,600 | 49,136,700 |
| Shares Held by Insiders | 6.16% | 11.6% |
| Shares Held by Institutions | 76.4% | 59.4% |
Scores
| Measure | Macrogenics | Industry median |
|---|---|---|
| Altman Z-Score | -3.86 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Macrogenics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.